Herantis Pharma Oyj (HRTIS.HE)
EUR 1.66
(0.91%)
EUR 1.66
(0.91%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 154.36 Thousand EUR | 101.93% |
| 2022 | -7.99 Million EUR | 35.87% |
| 2021 | -9.04 Million EUR | -54.37% |
| 2020 | -8.07 Million EUR | -12.81% |
| 2019 | -7.15 Million EUR | -46.91% |
| 2018 | -4.87 Million EUR | -23.47% |
| 2017 | -2.24 Million EUR | 10.76% |
| 2016 | -4.42 Million EUR | 72.66% |
| 2015 | -16.16 Million EUR | -111.14% |
| 2014 | -7.65 Million EUR | -917.59% |
| 2013 | -752.43 Thousand EUR | -98.17% |
| 2012 | -379.68 Thousand EUR | 73.58% |
| 2011 | -1.47 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.37 Million EUR | -153.79% |
| 2024 Q2 | -2.75 Million EUR | 0.0% |
| 2023 FY | 154.37 Thousand EUR | 101.93% |
| 2023 Q3 | 1.28 Million EUR | 153.21% |
| 2023 Q4 | 2.56 Million EUR | 99.97% |
| 2023 Q2 | -2.4 Million EUR | -100.0% |
| 2023 Q1 | -1.2 Million EUR | 65.33% |
| 2022 Q2 | -4.52 Million EUR | -106.91% |
| 2022 Q1 | -2.18 Million EUR | 52.41% |
| 2022 FY | -7.99 Million EUR | 35.87% |
| 2022 Q4 | -3.47 Million EUR | -91.67% |
| 2022 Q3 | -1.81 Million EUR | 59.91% |
| 2021 Q4 | -4.59 Million EUR | -100.01% |
| 2021 Q1 | -3.93 Million EUR | 5.19% |
| 2021 FY | -12.46 Million EUR | -54.37% |
| 2021 Q3 | -2.29 Million EUR | 59.7% |
| 2021 Q2 | -5.69 Million EUR | -44.71% |
| 2020 Q2 | -4.01 Million EUR | -100.0% |
| 2020 Q4 | -4.15 Million EUR | -104.54% |
| 2020 FY | -8.07 Million EUR | -12.81% |
| 2020 Q1 | -2 Million EUR | 52.56% |
| 2020 Q3 | -2.02 Million EUR | 49.43% |
| 2019 Q2 | -2.92 Million EUR | -100.0% |
| 2019 Q3 | -2.11 Million EUR | 27.73% |
| 2019 FY | -7.15 Million EUR | -46.91% |
| 2019 Q1 | -1.46 Million EUR | -24.18% |
| 2019 Q4 | -4.22 Million EUR | -100.0% |
| 2018 Q3 | -1.17 Million EUR | 6.28% |
| 2018 Q4 | -1.17 Million EUR | 0.0% |
| 2018 FY | -4.87 Million EUR | -23.47% |
| 2018 Q2 | -1.25 Million EUR | 0.0% |
| 2018 Q1 | -1.25 Million EUR | -29.45% |
| 2017 FY | -3.94 Million EUR | 10.76% |
| 2017 Q4 | -971.11 Thousand EUR | 0.0% |
| 2017 Q3 | -971.11 Thousand EUR | 3.01% |
| 2017 Q2 | -1 Million EUR | 0.0% |
| 2017 Q1 | -1 Million EUR | 45.8% |
| 2016 Q2 | -1.27 Million EUR | 0.0% |
| 2016 FY | -4.42 Million EUR | 72.66% |
| 2016 Q4 | -1.84 Million EUR | -97.11% |
| 2016 Q3 | -937.19 Thousand EUR | 26.37% |
| 2016 Q1 | -1.27 Million EUR | 47.74% |
| 2015 Q3 | -1.21 Million EUR | 82.26% |
| 2015 FY | -16.16 Million EUR | -111.14% |
| 2015 Q1 | -6.86 Million EUR | -128.29% |
| 2015 Q2 | -6.86 Million EUR | 0.0% |
| 2015 Q4 | -2.43 Million EUR | -100.0% |
| 2014 Q1 | -447.9 Thousand EUR | -248.76% |
| 2014 Q3 | -3 Million EUR | -151.85% |
| 2014 Q2 | -1.19 Million EUR | -166.6% |
| 2014 Q4 | -3 Million EUR | 0.0% |
| 2014 FY | -7.65 Million EUR | -917.59% |
| 2013 FY | -752.43 Thousand EUR | -98.17% |
| 2013 Q4 | -128.42 Thousand EUR | 0.0% |
| 2013 Q1 | -183.7 Thousand EUR | 0.0% |
| 2013 Q3 | -128.42 Thousand EUR | 58.82% |
| 2013 Q2 | -311.88 Thousand EUR | -69.78% |
| 2012 FY | -379.68 Thousand EUR | 73.58% |
| 2011 FY | -1.43 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Biohit Oyj | 1.82 Million EUR | 91.541% |
| Nanoform Finland Oyj | -22.47 Million EUR | 100.687% |